arrow
K

Kunyu Yang

macau university of science and technology信息科学技术学院 博导
H-index:51
Citation Count:1.0万
Views:0

Biography

康奇宇,中科大信息学院6系特任教授,博士生导师,国家青年人才。

Education

  • 2015.08 – 2020.03

    南洋理工大学 博士研究生

  • 2011.09 – 2015.07

    中国科学技术大学 本科

Work Experience

  • 2024.12 – 至今

    中国科学技术大学

    信息科学技术学院 博导

  • 2020.03 – 2024.11

    南洋理工大学

    博士后研究员

Honors & Awards

  1. 国家青年人才
The Goldilocks effect in hospitality teams: an investigation of the curvilinear relationship between shared leadership and service innovation

酒店团队中的“金发姑娘效应”:共享领导力与服务创新之间曲线关系的研究

2026-04-250
PRE
A prospective multicenter trial of deep learning auto-segmentation for organs at risk in thoracic radiotherapy

一项关于深度学习自动分割技术在胸部放射治疗中危及器官应用的 prospective multicenter trial。

2026-03-310
OAAI
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China

伊扎龙坦单抗培米替康,一种EGFR和HER3双特异性抗体-药物偶联物,与化疗在重度预治疗复发性或转移性鼻咽癌中的比较:一项在中国进行的多中心、随机、开放标签、III期研究

2025-10-190
PRE
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

一项关于OX40激动剂BGB-A445与或不与tislelizumab(一种抗PD-1单克隆抗体)联合治疗晚期实体瘤患者的I期研究:剂量递增结果

2025-10-080
OA
Treatment parameters consideration for universal range shifter-based multi-energy proton FLASH-RT

基于通用范围偏移器的高能多能量质子FLASH-RT的治疗参数考量

2025-09-300
PRE
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial

YK-029A在既往治疗过的EGFR T790M突变型NSCLC中的安全性与有效性:一项多中心I期临床试验

2025-09-230
OAAI
The mental health effects of smart city development on elderly residents: A quasi-natural experiment from China's smart city pilot policy

智能城市发展对老年居民心理健康的影响:来自中国智能城市试点政策的一项准自然实验

2025-08-270
PRE
Can green location-oriented policy enhance urban green innovation efficiency? Evidence from national ecological industrial demonstration parks

绿色区位导向政策能否提升城市绿色创新效率?——来自国家级生态工业示范园区的证据

2025-08-250
PRE
How artificial intelligence applications enhance enterprise green total factor productivity? A perspective on human-machine matching and labor skill structure

人工智能应用如何提升企业绿色全要素生产率?——基于人机匹配与劳动力技能结构的视角

2025-06-260
PRE
Radiation-induced upregulation of itaconate in macrophages promotes the radioresistance of non-small cell lung cancer by stabilizing NRF2 protein and suppressing immune response

辐射诱导的衣康酸在巨噬细胞中的上调通过稳定NRF2蛋白和抑制免疫反应促进非小细胞肺癌的放射抗性。

2025-06-030
OA
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial

卡瑞利珠单抗辅助PD-1阻断治疗鼻咽癌:DIPPER随机临床试验

2025-05-132
PRE
RETRACTION: β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma

撤回:β-Trcp和CK1δ介导的LZTS2降解激活PI3K/AKT信号通路,以驱动肝细胞癌中的肿瘤发生和转移

2025-03-170
OA
The role of high-tech certification in enterprise green innovation: from the perspectives of substantive innovation and strategic innovation

高新技术认证在企业绿色创新中的作用 -- 基于实质性创新和战略创新的视角

2025-03-100
OA
Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinoma

高级图像识别技术在鼻咽癌N分期中精炼咽后淋巴结外侵的进展

2025-02-010
OAAI
SMARCB1/INI-1-Deficient sinonasal carcinoma demonstrates a poor prognosis but favorable clinical outcomes after PD-1/PD-L1 inhibitor therapy: A case series

SMARCB1/INI-1缺乏性鼻窦癌表现出不良预后,但PD-1/PD-L1抑制剂治疗后临床结局良好:一例病例系列研究

2025-01-310
OA
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study

放疗暴露对 fruquintinib 联合 sintilimab 治疗难治性微卫星稳定型转移性结直肠癌的影响:一项前瞻性观察研究

2025-01-042
OA
Relieving immunosuppression during long-term anti-angiogenesis therapy using photodynamic therapy and oxygen delivery (vol 12, pg 14788, 2020)
2025-01-010
OA
The Impact of High-Tech Enterprise Certification on Green Innovation: Evidence from Listed Companies in China
2024-12-282
OA
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study

针对晚期肿瘤患者的PD-1和PD-L1的一流双特异性抗体IBI318 (LY3434172): Ia/Ib期研究

2024-11-290
OAAI
Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)

评估伊沃奈西单抗与利古法利单抗联合作为PD-L1阳性复发/转移性头颈鳞状细胞癌(R/M HNSCC)一线(1L)治疗的安全性和有效性

2024-09-011
PRE